Macrogenics Stock News

MacroGenics (MGNX) delivered earnings and revenue surprises of -14.46% and 28.67%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics press release (MGNX): FY GAAP EPS of -$3.37 misses by $0.10.Revenue of $77.45M (-26.2% Y/Y) misses by $6.13M.

ROCKVILLE, Md., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for t

ROCKVILLE, Md., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2021.

MacroGenics, Inc. (MGNX) CEO Scott Canning on Q4 2021 Results - Earnings Call Transcript

MacroGenics (MGNX) delivered earnings and revenue surprises of -14.46% and 28.67%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (NASDAQ: ADGI) announced th

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug A

Quidel (QDEL) delivered earnings and revenue surprises of 49.08% and 0.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ROCKVILLE, MD, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeu

ROCKVILLE, MD, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter of 2021 after the market closes on Thursday, February 24, 2022. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, February 24, 2022, at 4:30 pm ET. The conference call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the Conference ID# 1067087.

ROCKVILLE, MD, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeuti

MacroGenics Inc. (NASDAQ:MGNX) price on Friday, February 11, fall -6.79% below its previous days close as a downside momentum from buyers pushed the stocks value to $10.71. A look at the stocks price movement, the close in the last trading session was $11.49, moving within a range at $10.59 and $11.96. The beta value (5-Year Analysts Provide Insight Into MacroGenics Inc.s (MGNX) Potential. Read More »

Upgrades CBRE upgraded the previous rating for Penn National Gaming Inc (NASDAQ:PENN) from Hold to Buy. For the fourth quarter, Penn National Gaming had an EPS of $0.26, compared to year-ago quarter